Recurrent stroke predictors differ in medically treated patients with pathogenic vs other PFOs by Thaler, David E. et al.
DOI 10.1212/WNL.0000000000000589
 published online June 13, 2014Neurology 
David E. Thaler, Robin Ruthazer, Christian Weimar, et al. 
with pathogenic vs other PFOs
Recurrent stroke predictors differ in medically treated patients
This information is current as of June 13, 2014
http://www.neurology.org/content/early/2014/06/13/WNL.0000000000000589.full.html
located on the World Wide Web at: 
The online version of this article, along with updated information and services, is
Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of 
® is the official journal of the American Academy of Neurology. Published continuouslyNeurology 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
54
21
0 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
David E. Thaler, MD,
PhD
Robin Ruthazer, MPH
Christian Weimar, MD
Jean-Louis Mas, MD
Joaquín Serena, MD,
PhD
Emanuele Di
Angelantonio, MD,
MSc
Federica Papetti, MD
Shunichi Homma, MD
Heinrich P. Mattle, MD
Krassen Nedeltchev, MD
Marie-Luise Mono, MD
Cheryl Jaigobin, MD,
MSc
Patrik Michel, MD
Mitchell S.V. Elkind, MD
Marco R. Di Tullio, MD
Jennifer S. Lutz, MS, MS
John Griffith, PhD
David M. Kent, MD,
CM, MSc
Correspondence to
Dr. Thaler:
dthaler@tuftsmedicalcenter.org
Editorial, page XXX
Supplemental data
at Neurology.org
Recurrent stroke predictors differ in
medically treated patients with pathogenic
vs other PFOs
ABSTRACT
Objective: To examine predictors of stroke recurrence in patients with a high vs a low likelihood of
having an incidental patent foramen ovale (PFO) as defined by the Risk of Paradoxical Embolism
(RoPE) score.
Methods: Patients in the RoPE database with cryptogenic stroke (CS) and PFO were classified as
having a probable PFO-related stroke (RoPE score of.6, n5 647) and others (RoPE score of#6
points, n 5 677). We tested 15 clinical, 5 radiologic, and 3 echocardiographic variables for
associations with stroke recurrence using Cox survival models with component database as a
stratification factor. An interaction with RoPE score was checked for the variables that were
significant.
Results: Follow-up was available for 92%, 79%, and 57% at 1, 2, and 3 years. Overall, a higher
recurrence risk was associated with an index TIA. For all other predictors, effects were signifi-
cantly different in the 2 RoPE score categories. For the low RoPE score group, but not the high
RoPE score group, older age and antiplatelet (vs warfarin) treatment predicted recurrence. Con-
versely, echocardiographic features (septal hypermobility and a small shunt) and a prior (clinical)
stroke/TIA were significant predictors in the high but not low RoPE score group.
Conclusion: Predictors of recurrence differ when PFO relatedness is classified by the RoPE score,
suggesting that patients with CS and PFO form a heterogeneous group with different stroke
mechanisms. Echocardiographic features were only associated with recurrence in the high RoPE
score group. Neurology® 2014;83:1–6
GLOSSARY
CS 5 cryptogenic stroke; HR 5 hazard ratio; PFO 5 patent foramen ovale; PH 5 proportional hazard; RoPE 5 Risk of
Paradoxical Embolism; TEE 5 transesophageal echocardiography.
Randomized trials comparing endovascular patent foramen ovale (PFO) closure with antithrom-
botic therapy for stroke prevention in patients with cryptogenic stroke (CS) and PFO have been
equivocal1–3 and identify the importance of careful patient selection. Closure may only benefit
those with a high “PFO-attributable recurrence risk”—the joint probability that (1) the discov-
ered PFO was pathogenic (i.e., causally related to the index event) and (2) the CS will recur.
Identifying predictors of recurrence risk among those most likely to have had a PFO-related
index event is of high clinical interest.
Previously, we identified variables that are associated with PFO prevalence in CS patients.4
Based on this and Bayes theorem, we developed the Risk of Paradoxical Embolism (RoPE) score,
which estimates the probability that a PFO discovered in a CS patient is incidental or patho-
genic. Patients with high RoPE scores (younger, no vascular risk factors, and a superficial infarct)
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are more likely to have pathogenic PFOs, while
PFOs in patients with low RoPE scores (older
with vascular risk factors) are probably incidental.
We examined factors associated with recur-
rence risk in patients with PFO and CS. We
hypothesized that if RoPE scores segregate pa-
tients into those more and less likely to have
PFO-related index events, then predictors of
recurrence should differ between the groups.
Further, PFO characteristics (e.g., shunt size
and septal hypermobility) should be less influen-
tial in low RoPE score patients (PFO-unrelated
strokes). Such a findingwould indirectly validate
the RoPE score and ultimately provide a basis for
improving patient selection.
METHODS The design of the RoPE Study including model
derivation and validation, the details of the RoPE database, and
neuroimaging and echocardiographic findings have been
described previously.4–7 In brief, we created a database of 3,674
subjects with CS and known PFO status (all had transesophageal
echocardiography [TEE] or transcranial Doppler) by combining
existing cohort studies with protocol-driven follow-up. Index
events were sudden-onset neurologic deficits presumed due to
cerebral ischemia lasting longer than 24 hours or associated with
anatomically relevant radiologic lesions (stroke) or lasting less than
24 hours with normal imaging (TIA). The operational definition
of “cryptogenic” varied somewhat between databases but generally
adhered to the TOAST criteria. To be included in the database,
each cohort study was required to have aminimumof 85% follow-
up for 1-year outcome and sufficient clinical, echocardiographic,
and neuroradiologic data to permit multivariate modeling. Our
analyses are retrospective but come from the RoPE database,
which was formed by combining existing cohort studies, all of
which included prospectively collected data.
The clinical variables in the database are age (at index event),
sex, race, hypertension, diabetes, coronary artery disease, hyper-
cholesterolemia, smoking, a history of cerebral ischemia (TIA
or stroke) prior to the index event, medications being taken at
the time of the index event (antithrombotics, statins, hormone
replacement therapy, oral contraceptives), and treatment medica-
tions after the index event (antiplatelets, anticoagulants). The
echocardiographic variables used in this analysis are septal hyper-
mobility, PFO shunting at rest, and physiologic shunt size. De-
tails of how these data were measured in the component studies
and merged into the RoPE database have been described previ-
ously.5 Septal hypermobility refers to interatrial septal excursion
during the cardiac cycle of 10 mm or more from the midline.
Shunting at rest refers to agitated saline contrast (bubbles) appear-
ing in the left atrium within 3 cardiac cycles of right atrial opac-
ification with normal respiration, i.e., not requiring Valsalva
maneuver. Physiologic shunt size was defined by the maximal
number of bubbles seen in the left atrium either at rest or after
Valsalva maneuver. A large shunt was defined as greater than 10–
15 bubbles in a single frame. The neuroradiologic variables were
taken from imaging done at the time of the index event. They
were infarct seen (yes/no), infarct location (superficial, deep),
infarct size (large/small), multiple acute infarcts (yes/no), chronic
(prior) stroke (yes/no). Details of the neuroimaging findings in
RoPE have been described separately.6
Outcomes included stroke and TIA. Each outcome was re-
adjudicated by the RoPE Outcome Adjudication Committee and
categorized as stroke, TIA, nonstroke death, or no event.8 Cerebral
ischemic events were assigned a pathophysiologic mechanism if
possible. However, given the nature of the RoPE study, systematic
workups were not performed to determine mechanism across stud-
ies. All outcomes, irrespective of the adjudicated mechanism of
recurrence, were included for analysis. Sensitivity analysis was per-
formed excluding nonstroke outcomes (i.e., TIA) and recurrent
events of determined cause (i.e., ostensibly not PFO-related).
To support risk modeling, the database was divided into those
with RoPE scores of 0–6 (n 5 678, estimated PFO attributable
fraction 40% [36%–43%]) and 7–10 (n 5 646, estimated PFO
attributable fraction 80% [77%–83%]). The cohort was divided
into a high and low RoPE score group based on a threshold
approximating the median score to maximize power (#6 vs.6).
Patient characteristics were summarized. One- and 2-year
stroke/TIA recurrence rates were estimated using Kaplan-Meier
curves. To support Cox proportional hazard (PH) regression mod-
eling, we estimated missing data points using single imputation
based on the averaged results of 10multiply imputed databases. Sep-
arate Cox PH regression models were developed on each of these
strata using all the variables shown in table 1. Variables that were
significant at the p# 0.05 threshold in either model were included
as candidates together with their interaction with RoPE strata in a
model derived from the entire cohort. Variables were retained in
the model if their interaction term was significant at the p # 0.1
threshold or their main effect was significant at the p # 0.05
threshold.
Because some patients in the RoPE database were eventually
treated with mechanical closure, we examined the potential influ-
ence of informative censoring on our results, by (1) examining
patient characteristics of those closed compared to other study pa-
tients; (2) examining the impact of excluding these patients on
the results of the multivariable model; and (3) performing multi-
ple sensitivity analyses assigning stroke outcomes to the patients
who were censored due to closure, including incident rates con-
siderably higher than clinically anticipated.
Standard protocol approvals, registrations, and patient
consent. This study was approved by the Tufts Medical Center
internal review board.
RESULTS Demographics of the population are pre-
sented in table 1. Of the 3,674 subjects in the RoPE
database, there are 1,543 with PFO and adequate
study-level subject follow-up. We excluded 219
subjects because the PFO was not evaluated by TEE
(n 5 120), or because subjects did not have adequate
follow-up or outcome data (n 5 59), or consent for
follow-up was not obtained (n 5 40). The remaining
1,324 subjects had a median follow-up of 2.2 years
(interquartile range 1.0–3.6). More than 1 year follow-
upwas available for 93%.Of the 133 total outcomes, 11
were excluded as no event after the adjudication process,
leaving a total of 122 outcomes (76 stroke and 46 TIA)
for this analysis. A mechanism was identified for the
recurrent event in 5 subjects (3 stroke and 2 TIA) and
was either cryptogenic or lacked sufficient information
for adjudication in the remaining 117. All patients in the
database were under the care of study neurologists and
were treated with medical therapies, i.e., antithrombotic
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medication and risk factor modification according to
local practice.
The stroke/TIA recurrence rates differed by RoPE
strata. For those with low RoPE scores, the 1-year and
2-year rates were 7% and 10%, respectively, and only
4% and 5% for those with high RoPE scores (figure;
KM plot; p , 0.0001, log-rank test). Of the 5 recur-
rent events adjudicated as having a known cause, 4
were in the low RoPE score group.
Subjects presenting with TIA rather than stroke
had a higher risk for recurrence (hazard ratio [HR]
1.69, 1.05–2.74), but there was no interaction with
RoPE strata (table 2).
Other variables were associated with recurrence but
only in 1 RoPE stratum or another (interaction p value
#0.10). In those with low RoPE scores, there was an
increased risk of recurrence (1) with older age (HR
1.47, 1.18–1.83) and (2) in those who were treated
with antiplatelet drugs after their index event (HR
1.69, 1.05–2.74). These variables were not influential
in the high RoPE score stratum. There were 3 variables
that were only associated with recurrence in the high
RoPE score group: a history of stroke or TIA (HR
3.79, 1.43–10.09), a hypermobile interatrial septum
(HR 2.31, 1.05–5.05), and a small shunt (HR 3.26,
1.59–6.67) (table 2). Shunt at rest was not associated
with recurrence in either group. A sensitivity analysis
done after excluding the French study (in which the
association between a hypermobile interatrial septum
and recurrence risk was initially reported) did not
change the direction of the associations with the echo-
cardiographic variables. The characteristics of the 187
patients who were closed differed from those who con-
tinued with medical therapy by being younger, less
likely to smoke, less likely to have CAD, and more
likely to have been on anticoagulants at the time of
their incident event (table e-1 on the Neurology®
Web site at Neurology.org). However, sensitivity anal-
yses excluding these patients (table e-2) or randomly
assigning to them stroke outcomes at the time of
Table 1 Demographics of the population divided by RoPE Score strata
Full cohort (n 5 1,324) RoPE 1–6 (n 5 677) RoPE ‡7 (n 5 647)
Clinical
Age, y 49.8 6 14.6 60.1 6 10.9 39.0 6 9.2
Male 58.9 (780/1,324) 63.7 (431/677) 53.9 (349/647)
Incident event TIA 13.7 (182/1,324) 17.7 (120/677) 9.6 (62/647)
History of stroke/TIA before incident 11.9 (157/1,320) 18.5 (125/675) 5.0 (32/645)
History of coronary artery disease 7.0 (64/911) 10.1 (56/555) 2.2 (8/356)
History of hypercholesterolemia 24.1 (247/1,027) 35.8 (182/509) 12.5 (65/518)
Current/recent smoker 29.4 (386/1,312) 32.2 (215/667) 26.5 (171/645)
Antiplatelets at incident event 11.2 (120/1,072) 18.8 (98/520) 4.0 (22/552)
Anticoagulants at incident event 2.4 (21/872) 3.6 (15/411) 1.3 (6/461)
Statins at incident event 15.8 (44/279) 21.5 (38/177) 5.9 (6/102)
Radiology
Radiology finding of prior stroke 21.5 (192/891) 33.0 (148/448) 9.9 (44/443)
Superficial strokea 57.0 (482/845) 47.9 (210/438) 66.8 (272/407)
Radiology finding of multiplea 18.3 (144/787) 17.6 (67/380) 19.3 (77/400)
Radiology finding of large strokea 66.0 (471/717) 63.4 (251/396) 68.5 (220/321)
Echocardiography
Large shunt 64.4 (695/1,079) 61.2 (344/562) 67.9 (351/517)
Hypermobile interatrial septum 25.3 (320/1,265) 27.4 (175/638) 23.1 (145/627)
Shunt at rest 69.6 (484/695) 71.6 (244/341) 67.8 (240/354)
Treatment and outcomes
Treated with antiplatelets 54.0 (706/1,307) 59.0 (395/670) 48.8 (311/637)
Treated with anticoagulants 51.1 (667/1,306) 45.6 (305/669) 56.8 (362/637)
Outcomes: stroke or TIA 9.2 (122/1,324) 12.9 (87/677) 5.4 (35/647)
Abbreviations: CS 5 cryptogenic stroke; HR 5 hazard ratio; PFO 5 patent foramen ovale; PH 5 proportional hazard; RoPE 5 Risk of Paradoxical Embolism;
TEE 5 transesophageal echocardiography.
Values are mean 6 SD or % (n).
a Subjects with TIA excluded.
Neurology 83 July 15, 2014 3
ª 2014 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
closure at rates considerably higher than those other-
wise anticipated showed that our main results were
robust to the full range of plausible outcome rates in
these patients (appendix e-1).
DISCUSSION Our analysis shows that patients with
CS and PFO have different risk factors for short-term
recurrence when segregated by RoPE score strata.
Those with low RoPE scores (indicating that the
index event was less likely to be PFO-related) have
recurrent strokes in association with a conventional
vascular risk factor (i.e., age) with no clear influence
from the echocardiographic characteristics of their
probable incidental PFOs. On the other hand, the
echocardiographic characteristics of the PFOs in those
with high RoPE scores are strongly associated with
recurrence. This suggests different stroke mechanisms
for these different strata; the importance of echocardio-
graphic factors seen in the high RoPE score patients
provides confirmatory evidence for the PFO-relatedness
of the initial stroke in these patients.
A limitation in using the RoPE score alone to
select patients for percutaneous closure is that those
patients with high RoPE scores were found to be at
much lower risk for stroke recurrence compared to
those with low RoPE scores.4 Thus, while low RoPE
score patients might be expected to have limited ben-
efit from closure because a large proportion of the
index events are due to mechanisms unrelated to the
PFO and unaddressed by closure, high RoPE score
patients may have limited benefit because they are
unlikely to have recurrent strokes when treated
medically.
In CS patients, a prior clinical history of stroke is
less common (;10%) than is a chronic stroke seen
at the time of index event imaging (;25%).6 Both
are associated with recurrence but the clinical history
appears especially influential in the high RoPE score
group. This suggests that high RoPE score patients
who present with recurrent stroke are at a particularly
high risk of another event. In both RoPE strata, how-
ever, TIA again shows itself to be an unstable cerebro-
vascular condition with a higher risk of recurrence than
in those with a definitive stroke.9
The observation that echocardiographic characteris-
tics are only influential in the high RoPE score group is
intuitive and was anticipated. A hypermobile (“aneu-
rysmal”) interatrial septum has been implicated as a
risk factor for recurrent stroke since the 2001 article
Figure Kaplan-Meier plot of recurrent stroke-free survival by Risk of
Paradoxical Embolism (RoPE) stratum
Table 2 Adjusted hazard ratios from multivariable model of recurrent stroke/TIA
Variable
Adjusted hazard ratio (95% confidence interval)
Interaction
p valuea
Point score £6
(raw event rate: 87/677 5 13%)
Point score >6
(raw event rate: 35/647 5 5%)
Age (linear), hazard ratio per 10-y increase 1.47 (1.18–1.83)b 0.83 (0.57–1.20) 0.0083
Treated with antiplatelets 1.69 (1.05–2.74)b 0.74 (0.37–1.48) 0.0554
History of prior stroke or TIA 1.58 (0.89–2.44) 3.79 (1.43–10.09)b 0.0911
Small shunt 1.29 (0.82–2.03) 3.26 (1.59–6.67)b 0.0306
Hypermobile interatrial septum 0.83 (0.49–1.42) 2.31 (1.05–5.05)b 0.0350
All subjects (raw event rate: 122/1,324 [9%])
Incident TIA (vs stroke) 1.69 (1.05–2.74)b
Hazard ratio .1 indicates positive association with outcome.
a If the p value of the variable or the interaction with the categorized point score (#6, .6) was #0.10, then the interaction
term was left in the model and hazard ratios were estimated separately for the point score subgroups. If the interaction
p value was $0.10, then the interaction term was not included in the model and a single hazard ratio for the variable was
estimated.
b95% Confidence interval for hazard ratio is above or below 1 (with a corresponding p value of #0.05).
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by Mas et al.8 We confirm that finding, although we
note that those data formed part of the RoPE dataset.
Our result that there is a strong relationship be-
tween smaller shunt size and recurrent stroke is coun-
terintuitive and was unanticipated. The finding could
be argued to be a consequence of an unreliable
variable—interobserver agreement for grading shunt
size was only moderate.8 Furthermore, physiologic
shunt size can vary from day to day and is dependent
on hydration status, technical factors during the injec-
tion of the agitated saline, and patient cooperation,
especially with Valsalva.10 However, lack of reliability
or consistency in shunt grading should produce a bias
toward the null, and thus is unlikely to explain the
discovery of a strong association, albeit in an unex-
pected direction.
Conventional wisdom has it that a larger shunt
supports the initial diagnosis of PFO-relatedness and
also identifies those at higher risk of recurrence.
Indeed, others have found that PFOs discovered in
CS patients are more frequently large than those dis-
covered in patients with stroke of known cause.11 This
finding, however, does not necessarily imply that pa-
tients with larger shunts therefore are at a higher risk
of recurrence. Indeed, in the PICSS trial, for example,
large shunt was a risk factor for stroke at the index
event, but not for stroke recurrence. Our finding that
small shunts are associated with an increased risk of
recurrence in those without conventional vascular risk
factors highlights the importance of considering that
mechanisms other than paradoxical embolism (e.g., in
situ thrombus) may also play a role in the association
of PFO with CS, as others have also noted.12
Our findings also highlight the need for clarity
regarding the definition of “high-risk” PFO patients.
The literature on this issue is confusing. It is common
that authors conflate the factors associated with the
confidence of a PFO-associated diagnosis (e.g., youn-
ger age, CS, absence of vascular risk factors, peripher-
ally located brain infarcts) with the risk for recurrence
and some have made treatment recommendations on
the basis of this. One such article relied on 11 refer-
ences to support the features that the authors identified
as “associated with recurrent paradoxical events.”13 Of
those 11 references, 6 were without recurrence data
entirely, 4 were not CS populations, and 1 was a CS
population with no recurrent events.
This analysis is limited by the potential variability
of protocols and definitions within the different studies
that comprise the RoPE database. Efforts were made to
harmonize the variables but some misclassification is
inevitable. There still is no standardized approach for
describing PFO anatomical and physiologic character-
istics by transesophageal echocardiography, the absence
of which hampers studies like ours. There are other var-
iables that may be related to recurrence risk but that
were not uniformly available in the component datasets
and so were excluded for this analysis. Variables, such
as hypercoagulable states, Valsalva-like activities imme-
diately prior to symptom onset, and exogenous hor-
mone therapy, could be tested in subgroups in future
analyses. These database limitations also apply to the
RoPE score itself, which does not include all potentially
important variables for distinguishing patients with
pathogenic vs incidental PFOs. Nevertheless, the study
shows that this score appears to identify subgroups of
patients with greatly different risks of recurrence and
different determinants of recurrence. This is consistent
with our hypothesis that the score disaggregates CS pa-
tients into groups likely to have different mechanisms.
Other limitations include the fact that our statisti-
cal power was decreased by excluding 601 subjects
from the RoPE database for reasons mentioned above.
Power was also reduced by the relatively short mean
follow-up in the entire dataset, although some subjects
were followed for as long as 15 years. Predictors of
stroke over longer periods of time than is available
in the RoPE database may not be the same as those
identified here. However, later follow-up will, by def-
inition, be in older patients in whom competing
mechanisms of stroke become more common. There-
fore, PFO-related variables may become less influen-
tial. Finally, we were unable to subclassify most of
the recurrent events, thus limiting our ability to deter-
mine PFO or other relatedness.
Among patients with CS and PFO, stroke recur-
rence rates are higher in the stratum least likely to
have a PFO-attributable CS and lower in the stratum
most likely to have a PFO-attributable CS. Recur-
rence predictors differ by RoPE strata, suggesting dif-
ferent mechanisms in these groups. Echocardiographic
characteristics predict recurrence risk only in those
with high, but not low, RoPE scores. In those with
RoPE scores of 7 or greater, hypermobile interatrial
septa and smaller shunts are predictive of stroke recur-
rence, suggesting that paradoxical embolism is respon-
sible for only some of the PFO-associated strokes.
These data have implications for patient selection that
are contrary to recommendations made by consensus
rather than by reliable models of stroke recurrence.14
However, in order to use the information in this anal-
ysis for better patient selection, our predictive models
should be optimized into a single score that will strat-
ify patients by “PFO-attributable recurrence risk”—a
combination of (1) predictors of attributable fraction
and (2) predictors of recurrence risk. This should then
be tested on the extant randomized clinical trial data,
as we plan to do in subsequent studies.7
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